page_banner

Products

Citicoline sodium Cas:33818-15-4 CYTIDINE-5′-DIPHOSPHOCHOLINE

Short Description:

Catalog Number: XD90590
Cas: 33818-15-4
Molecular Formula: C14H25N4NaO11P2
Molecular Weight: 510.31
Availability: In Stock
Price:  
Prepack: 1g USD20
Bulk Pack: Request Quote

 


Product Detail

Product Tags

Catalog Number XD90590
Product Name Citicoline sodium

CAS

33818-15-4

Molecular Formula

C14H25N4NaO11P2

Molecular Weight

510.31
Storage Details -20°C
Harmonized Tariff Code 29349990

 

Product Specification

Appearance White Solid

Assay

99%

Melting point

250°C(dec.)(lit.)

Boiling point

°Cat760mmHg

PSA

238.17000

logP

-0.14090

Solubility

H2O: 100mg/mL

 

Citicoline (CDP-choline) is a key intermediary in the biosynthesis of phosphatidylcholine, an important component of the neural cell membrane. It has been shown to produce beneficial effects in both animal models and non-US clinical stroke trials. This study comprised a randomized (3 doses of citicoline to 1 placebo), vehicle-controlled, double-blind trial at 21 US centers. Treatment was to be started within 24 hours of stroke onset and was continued orally for 6 weeks. Final outcome assessments were at 12 weeks. Two hundred fifty-nine patients were enrolled, with approximately 65 in each of the four groups. Mean time from stroke onset to treatment was 14.5 hours, and there were no significant differences in baseline characteristics between the four groups except for patient weight. A significant difference between the groups, favoring citicoline treatment, was seen in terms of functional outcome as measured by the Barthel Index and Rankin scale, neurologic evaluation as measured by the National Institutes of Health (NIH) stroke scale, and cognitive function as measured by the Mini Mental Status Examination. When the baseline NIH stroke scale was used as a covariate, both the 500-mg citicoline group and the 2,000-mg citicoline group had a significant improvement in terms of the percent of patients who had a favorable outcome on the Barthel Index at 90 days. There were no drug-related serious adverse events or deaths in this study. This study suggests that oral citicoline can be used safely with minimal side effects in acute stroke treatment. Citicoline appears to improve functional outcome and reduce neurologic deficit with 500 mg of citicoline appearing to be the optimal dose.


  • Previous:
  • Next:

  • Close

    Citicoline sodium Cas:33818-15-4 CYTIDINE-5′-DIPHOSPHOCHOLINE